JPMorgan Chase & Co. Reduces Stake in Liquidia Co. (NASDAQ:LQDA)

JPMorgan Chase & Co. lessened its stake in Liquidia Co. (NASDAQ:LQDA - Free Report) by 88.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,205 shares of the company's stock after selling 207,188 shares during the period. JPMorgan Chase & Co.'s holdings in Liquidia were worth $332,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC acquired a new stake in Liquidia in the 4th quarter valued at $59,000. EntryPoint Capital LLC acquired a new stake in shares of Liquidia in the fourth quarter valued at about $154,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Liquidia during the fourth quarter worth about $169,000. Arizona State Retirement System raised its position in shares of Liquidia by 20.3% during the 4th quarter. Arizona State Retirement System now owns 15,888 shares of the company's stock worth $187,000 after purchasing an additional 2,685 shares during the last quarter. Finally, DMC Group LLC boosted its holdings in Liquidia by 17.4% in the 4th quarter. DMC Group LLC now owns 16,302 shares of the company's stock worth $192,000 after buying an additional 2,419 shares during the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Liquidia

In related news, insider Jason Adair sold 1,856 shares of the company's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $25,185.92. Following the sale, the insider now directly owns 184,304 shares of the company's stock, valued at $2,501,005.28. This represents a 1.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Rajeev Saggar sold 2,450 shares of the firm's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $13.67, for a total transaction of $33,491.50. Following the completion of the transaction, the insider now directly owns 263,152 shares of the company's stock, valued at $3,597,287.84. This represents a 0.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,138 shares of company stock worth $450,233 over the last ninety days. Company insiders own 30.10% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and issued a $29.00 price target on shares of Liquidia in a research note on Thursday, March 20th. Needham & Company LLC reaffirmed a "buy" rating and set a $25.00 target price on shares of Liquidia in a report on Thursday, April 10th. Finally, Scotiabank increased their target price on shares of Liquidia from $34.00 to $36.00 and gave the company a "sector outperform" rating in a research report on Monday. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $26.88.

Liquidia Stock Down 3.4 %

NASDAQ:LQDA traded down $0.55 on Tuesday, reaching $15.57. The company's stock had a trading volume of 1,343,841 shares, compared to its average volume of 995,772. Liquidia Co. has a 12-month low of $8.26 and a 12-month high of $16.81. The stock has a 50 day moving average price of $14.23 and a 200 day moving average price of $13.06. The firm has a market cap of $1.33 billion, a price-to-earnings ratio of -9.55 and a beta of 0.24.

Liquidia (NASDAQ:LQDA - Get Free Report) last posted its earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.08). The company had revenue of $2.92 million during the quarter, compared to analyst estimates of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. Equities research analysts expect that Liquidia Co. will post -1.51 EPS for the current fiscal year.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).